Recent Updates — ERNA

Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D., to its Board of Directors effective September 14, 2026, following a recommendation by the Nominating and Corporate Governance Committee. Dr. Spiegel will serve until his successor is elected or until earlier death, resignation, or removal. He will be compensated under the Company’s existing Board of Directors Compensation Plan adopted on August 15, 2026. No arrangements exist between Dr. Spiegel and other persons regarding his appointment, nor are there family relationships with current directors or executive officers. The company operates in the biotechnology industry, focusing on drug discovery and development.

Sandra Gurrola, Senior Vice President of Finance, resigned from Ernexa Therapeutics Inc. effective July 3, 2026. She will provide part-time transition assistance for up to 10 hours per week until the filing of the Q2 2026 Form 10-Q. Ernexa Therapeutics Inc. is a biotechnology company focused on developing therapeutic solutions.